Catalyst Pharma reports record 2023 revenue of $398.2M (+85.9% YoY); non-GAAP EPS $1.96

CATALYST PHARMACEUTICALS, INC.

2023-FY EPS reported $0.63 revenue$398,204,000

Q4 2023 total revenue $110.6M (+82% YoY); full-year GAAP net income $71.4M ($0.63 diluted).
Non-GAAP net income $223.2M ($1.96 diluted) vs. $113.9M ($1.02) in 2022, up 96%.
FIRDAPSE net revenue $258.4M (+20.8%); FYCOMPA contributed $138.1M since acquisition.
AGAMREE FDA approval for Duchenne MD; commercial launch on track for Q1 2024.
FY2024 total revenue guidance $455M-$475M, implying ~14-19% growth vs. 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.